ANKRD26 (ankyrin repeat domain 26) functions as a critical regulator of normal hematopoiesis, particularly in megakaryocyte, erythroid, and granulocyte differentiation 1. The protein is expressed during early stages of myeloid progenitor cell proliferation and is progressively silenced as differentiation proceeds to complete cellular maturation 1. ANKRD26 mechanistically interacts with and modulates the activity of type I cytokine receptors including MPL, EPOR, and G-CSFR, preventing their internalization and leading to increased signaling and cytokine hypersensitivity when overexpressed 1. Additionally, ANKRD26 localizes to centrosomes where it serves as an adapter for the PIDDosome complex, playing a role in caspase-2-mediated apoptosis of cells with extra centrosomes 2. Disease-wise, germline mutations in ANKRD26's 5' untranslated region cause thrombocytopenia 2 (THC2), an autosomal dominant inherited thrombocytopenia characterized by moderate platelet reduction with normal size and mild bleeding tendency 34. These mutations prevent normal transcriptional downregulation by RUNX1 and FLI1, leading to sustained ANKRD26 expression 3. Clinically, ANKRD26-related thrombocytopenia predisposes patients to hematologic malignancies, particularly acute myeloid leukemia and myelodysplastic syndrome, necessitating multidisciplinary surveillance approaches 45.